These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1643698)

  • 1. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
    Bailey H; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Grem JL; Spriggs DR
    Cancer Chemother Pharmacol; 1992; 30(4):297-302. PubMed ID: 1643698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
    Remick SC; Grem JL; Fischer PH; Tutsch KD; Alberti DB; Nieting LM; Tombes MB; Bruggink J; Willson JK; Trump DL
    Cancer Res; 1990 May; 50(9):2667-72. PubMed ID: 2328492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
    Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
    Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
    Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
    Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
    Köhne CH; Hiddemann W; Schüller J; Weiss J; Lohrmann HP; Schmitz-Hübner U; Bodenstein H; Schöber C; Wilke H; Grem J
    J Clin Oncol; 1995 May; 13(5):1201-8. PubMed ID: 7738622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens.
    Tsavaris N; Kosmas C; Polyzos A; Genatas K; Vadiaka M; Paliaros P; Dimitrakopoulos A; Rokana S; Karatzas G; Vachiotis P; Fotiadis K
    Tumori; 2001; 87(5):303-7. PubMed ID: 11765178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.
    Bjarnason GA; Kerr IG; Doyle N; Macdonald M; Sone M
    Cancer Chemother Pharmacol; 1993; 33(3):221-8. PubMed ID: 8269603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of 5-fluorouracil and high-dose leucovorin in gastric carcinoma and a phase I trial of intraperitoneal 5-fluorouracil and leucovorin.
    Arbuck SG; Douglass HO; Trave F; Rustum YM
    NCI Monogr; 1987; (5):203-5. PubMed ID: 3501544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.
    Danhauser LL; Freimann JH; Gilchrist TL; Gutterman JU; Hunter CY; Yeomans AC; Markowitz AB
    J Clin Oncol; 1993 Apr; 11(4):751-61. PubMed ID: 8478667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies.
    Bruckner HW; Petrelli NJ; Stablein D; Novak J; Mayer R
    NCI Monogr; 1987; (5):179-84. PubMed ID: 3501539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
    Kelsen DP; Saltz L; Cohen AM; Yao TJ; Enker W; Tong W; Tao Y; Bertino JR
    Cancer; 1994 Oct; 74(8):2224-33. PubMed ID: 7922973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
    Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
    Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    Riva C; Lavieille JP; Schmerber S; Cuisnie O; Reyt E
    Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid.
    Budd GT; Jayaraj A; Grabowski D; Adelstein D; Bauer L; Boyett J; Bukowski R; Murthy S; Weick J
    Cancer Res; 1990 Nov; 50(22):7206-11. PubMed ID: 2224854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.